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Abstract Tibolone, a tissue-selective compound with a
combination of estrogenic, progestagenic, and androgenic
properties, is used as an alternative for estrogen or estrogen
plus progesterone hormone therapy for the treatment of
symptoms associated with menopause and osteoporosis.
The current study compares the endometrial gene expres-
sion profiles after short-term (21 days) treatment with
tibolone to the profiles after treatment with estradiol-only
(E2) and E2 + medroxyprogesterone acetate (E2 +M P A )i n
healthy postmenopausal women undergoing hysterectomy
for endometrial prolapse. The impact of E2 treatment on
endometrial gene expression (799 genes) was much higher
than the effect of tibolone (173 genes) or E2 +M P A
treatment (174 genes). Furthermore, endometrial gene
expression profiles after tibolone treatment show a weak
similarity to the profiles after E2 treatment (overlap 72
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urogenital tract.genes) and even less profile similarity to E2 +M P A
treatment (overlap 17 genes). Interestingly, 95 tibolone-
specific genes were identified. Translation of profile
similarity into biological processes and pathways showed
that ER-mediated downstream processes, such as cell cycle
and cell proliferation, are not affected by E2 + MPA,
slightly by tibolone, but are significantly affected by E2.I n
conclusion, tibolone treatment results in a tibolone-specific
gene expression profile in the human endometrium, which
shares only limited resemblance to E2 a n de v e nl e s s
resemblance to E2 + MPA induced profiles.
Keywords Tibolone.Endometrium.Hormonereplacement
therapy.Estrogen.Progestagen.Geneexpressionprofiling
Introduction
Unopposed estrogen treatment increases the risk for endo-
metrial hyperplasia and subsequent carcinoma. For example
in the HOPE study (Women’s Health, Osteoporosis, Proges-
tin, Estrogen study [1, 2]) after 2 years of treatment with
conjugated equine estrogens (CEE; 0.625 mg/day), the rate
of hyperplasia went up to 27.7%. When the treatment was
combined with medroxyprogesterone acetate (MPA;
2.5 mg), incidence of endometrial hyperplasia decreased
to the baseline incidence. Thus, the addition of progesta-
gens is necessary for endometrial safety. Progestagen
addition, however, also causes negative side effects like
withdrawal bleeding and an increased breast cancer
incidence that was recently documented in the Women’s
Health Initiative [3] and Million Women Study [4].
Tibolone is a synthetic steroid with a unique clinical
profile within the currently available postmenopausal
therapeutic options. Tibolone shows a tissue-selective mode
of action; in the vagina, brain, and bone, tibolone acts as an
estrogen, whereas no or slight estrogenic stimulation has
been found in breast and endometrium [5–7]. The tissue-
selective mode of action of tibolone and its metabolites is
due to the interplay between several mechanisms including
tissue-selective metabolism, enzymatic inactivation or
activation, and differential receptor binding.
During passage through the gastrointestinal tract and the
liver, tibolone is converted into three metabolites: two OH-
metabolites, 3α-OH-tibolone and 3β-OH-tibolone (exerting
estrogenic effects and in vivo present in large amounts) [8],
and the Δ
4-isomer (exerting progestagenic and androgenic
effects, and in vivo in plasma only present for a relatively
short period of time) [5, 9]. Besides the metabolism in the
liver and intestine, metabolism of tibolone also takes place
inside target tissues. For example, the lack of stimulation of
the human endometrium after long-term tibolone treatment
may partly be explained by the dominant presence of the
Δ
4-isomer of tibolone. Evidence in support of this tissue-
selective metabolism has been found in several in vitro test
systems. Tang et al. [10] have demonstrated that tibolone
can locally be converted in endometrial explants to the Δ
4-
isomer, and conversion of the 3-OH-metabolites back to
tibolone, and subsequently to the Δ
4-isomer, is another
possible mechanism that contributes to the local formation
of Δ
4-isomer [11]. Furthermore, our own work showed that
in an endometrial cancer cell line, the presence of bioactive
Δ
4-isomer could indeed effectively counteract the estro-
genic activity of tibolone [12, 13] resulting in a clear
predominant progestagenic effect.
In vivo, long-term tibolone use has been shown not to
stimulate the human endometrium, although in clinical
practice, especially at the beginning of a treatment,
increased episodes of spotting and bleeding are observed.
In a clinical study, for the first time, we investigated the
short-term (21 days) effects of tibolone on endometrial
histology and gene expression. Previously, we published
the histological data [14] and biochemical findings [15],
and now we present the molecular changes observed by
analyzing gene expression profiles. The effects of short-
term (21 days) treatment with tibolone were compared to
the effects of estradiol alone (E2) and E2 + MPA.
Materials and methods
Participants
This study was designed as a controlled clinical trial. The trial
was registered with National Institutes of Health, registry
number NCT00294463, found at http://www.clinicaltrials.
gov, under the name of Effects of Tibolone Treatment on the
Endometrium. Patients who visited our clinics to undergo
vaginal hysterectomy for treatment of prolapse were eligible
to participate in this study. A description of the inclusion and
exclusion criteria and the histological findings of the current
experiments were documented earlier [14].
The trial was performed in the period before the
scheduled surgery. After informed consent, the patients
were sequentially assigned to one of the following
treatment groups: control group (no hormonal treatment);
tibolone group (2.5 mg tibolone (Livial, N.V. Organon,
Oss, The Netherlands) administered orally every day,
starting 21 days prior to surgery); E2 group (2 mg of
estradiol administered orally every day, starting 21 days
before surgery); E2 + MPA group (2 mg estradiol + 5 mg
MPA administered orally every day, starting 21 days before
surgery). The investigators were kept blinded to the patient
treatments during sex hormone-binding globulin (SHBG)
measurements (Fig. 1), the cluster and correlation (Fig. 2)
analyses, and during validation reverse transcription poly-
472 J Mol Med (2007) 85:471–480merase chain reaction (RT-PCR; Fig. 4). Investigations
were conducted in accordance with the guidelines in The
Declaration of Helsinki, and the local ethics committees of
the participating hospitals approved the study protocol.
Measurement of sex hormone-binding globulin
Sera were collected before the start of treatment and at
surgery, processed and stored at −20°C until measurement.
SHBG was measured in sera of the different patient groups
by ABL (Assen, The Netherlands) with a commercially
available and validated AutoDelphia immunoassay and
using the automatic Delfia system 1235 (Wallac Oy, Turku,
Finland). The accuracy ranged from 101.1 to 110.9% with a
coefficient of variation expressed as percentage of the mean
of 1.5–1.8%. By measuring the SHBG values we were able
to verify compliance of the patients to the treatments.
Isolation of pure endometrial tissue and subsequent RNA
isolation
Immediately after hysterectomy (within 10 min), part of the
uterus was dissected and snap-frozen for RNA isolation.
Frozen tissue samples were embedded and 5-μms e c t i o n s
were collected in batches of ten. Each first and last section in
such a series was stained and evaluated under the microscope
for the percentage of endometrium and myometrium. Only
those batches with 100% pure endometrial tissue were
selected for RNA isolation. Tissues were homogenized by
sonication and RNA was isolated using Trizol (Invitrogen,
Life Technologies, Philadelphia, PA, USA). The concentra-
tion, quality, and purity of RNAwere assessed with the use of
the RNA 6000 Nano assay on the Agilent 2100 Bioanalyzer
(Agilent, Palo Alto, CA, USA). Only those RNA samples that
showed no sign of degradation or contamination by DNA
were used for gene expression profiling.
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Fig. 2 Cluster and correlation analyses of endometrial gene
expression profiles obtained after short-term (21 days) treatment
with E2,E 2 + MPA, or tibolone. Using statistical analysis, it was
established that 3,293 probe sets (representing 2,312 known and 466
unknown genes) deviated at least threefold, in at least one patient
sample, from the geometrical means of all treated samples. These
genes were used for the cluster and correlation analyses. a At the
bottom of the figure, relatedness is indicated. Red indicates genes with
a higher expression relative to the geometrical means, while blue
indicates genes with a lower expression relative to the geometrical
means. The numbers (#) behind the treatments indicate the patient
numbers. b The correlation values are between 1 (dark red, diagonal
line) and −1( dark blue, not represented here). The white boxes
represent no correlation between profiles
Fig. 1 SHBG measurements before and after treatment. Sera were
collected for each patient just before the start of treatment (pre) and
21 days later just before hysterectomy (post). The bold lines represent
the averages of the measured values
J Mol Med (2007) 85:471–480 473Gene expression profiling
Gene expression profiles of samples were generated with
the use of Affymetrix U133plus2 GeneChips containing
54,614 probe sets, representing approximately 47,000
transcripts (Affymetrix, Santa Clara, CA, USA). One
microgram of total RNA was used to prepare antisense
biotinylated RNA according to the Affymetrix protocol for
gene chip experiments (http://www.affymetrix.com). The
level and quality of cRNA was measured on the Agilent
2100 Bioanalyzer (Agilent). If a cRNA sample showed any
abnormal pattern, this sample was not used for further
analysis and new cRNA was generated. The cRNA was
fragmented with the GeneChip Sample Cleanup Module
(Affymetrix). Hybridization, staining, washing, and scan-
ning procedures were carried out as described in the
GeneChip Expression Analysis technical manual (Affyme-
trix). All GeneChips were visually inspected for irregular-
ities. All array data is freely accessible from the Erasmus
University Medical Center database (ENDO_GROUP_
PDATA at http://www.gatcplatform.nl/).
Data analyses
Similarity and correlation between expression profiles
Data normalization was done according to the quantile
method [16]. Subsequently, all intensity values below 30
were set at 30, since our methods reliably identify samples
with an average intensity value of 30 or more but do not
reliably discriminates values between 0 and 30. For each
probe set, the geometrical mean of the hybridization
intensities of all samples from the subjects was calculated.
The level of expression of each gene in every sample was
determined relative to this geometric mean and logarithmi-
cally transformed (on a base 2 scale) to assign equal weight
to gene expression levels with similar relative distances to
the geometrical mean. Deviation from the geometrical mean
reflects differential gene expression. Genes whose level of
expression differed at least threefold, in at least one sample
from the geometrical means of all treated samples (reflecting
up- or downregulation), were selected for further analysis.
The similarity and correlation between expression
profiles of different treatment groups was investigated with
the use of cluster analysis and the Pearson’s correlation and
Visualization tool of Omniviz (Ominviz, Maynard, MA,
USA; version 3.8).
Identification of genes with significant differential
expression
We used significance analysis of microarrays (SAM) [17],
implemented in Omniviz to determine genes with signifi-
cantly differential expression between the treatment groups.
SAM is a statistical method for identifying differentially
expressed genes while controlling the overall false discov-
ery rate (FDR). FDR is the percentage of genes identified
by chance. We have chosen the settings for this analysis in
such a way that the total number of falsely identified
differential expressed genes was less than 1 (this means
that the p value for a certain SAM analysis is smaller than
1/number of calculated differentially expressed genes).
Functional and biological classification of genes
The classification of genes into biological processes
and functional analyses was done using DAVID (http://
david.abcc.ncifcrf.gov), Panther (http://www.panther.
appliedbiosystems.com), and Ingenuity Pathway software
(http://www.ingenuity.com). In order to identify biological
processes with significantly enriched or depleted gene
numbers, the distribution of genes in each hormone-
regulated gene list for a particular biological process was
compared to that in a reference gene list. Since an
inappropriate reference list would lead to wrongful identi-
fication of regulated biological processes, we used two
reference lists: the Affymetrix 133Uplus2 gene list and the
NCBI human gene list (n=23,481). The enrichment or
depletion of genes, compared to the NCBI reference list, in
a certain biological process indicates significant hormonal
regulation (p<10
−4). The reason for using different classi-
fication software and databases was to verify consistency of
classification and to enhance reliability of the results.
Real-time quantitative PCR verifications
Validation of microarray expression data was accomplished
by real-time quantitative PCR (RT-qPCR) on ten selected
genes: CCND1 (cyclinD1), ERα (estrogen receptor α), ERβ
(estrogen receptor β), TFF3 (Trefoil factor 3), IGFBP3
(insulin-like growth factor binding protein 3), IGF1
(insulin-like growth factor 1), VEGF (vascular endothelial
growth factor), PR (progesterone receptor), CSPG2 (versi-
can), HSD17B2 (hydroxysteroid [17] dehydrogenase 2).
RT-qPCR was done as previously described [18]. The
sequences of primers and probes used in this study are
available upon request.
Results
Participants
In total, 30 out of 33 eligible postmenopausal patients
participated in this study. The E2 group originally included
eight subjects, but one patient was excluded on the basis of
474 J Mol Med (2007) 85:471–480a double layer endometrial thickness preceding 4 mm. The
E2 + MPA group originally also included eight subjects, but
one patient was excluded on the basis of an abnormal
cervical Pap smear test, while another patient had to be
excluded because her surgery was rescheduled. Patients in
the different groups were comparable with respect to age,
number of menstrual years, years after menopause, endo-
metrial thickness, and body mass index at screening [14].
Different steroid hormone treatments have been reported
in the literature to result in specific changes in the SHBG
concentrations: estrogen treatment will result in an increase
in the SHBG levels while tibolone’s androgenic actions in
the liver will result in a reduction of the SHBG levels [19].
Therefore, SHBG levels were measured in serum because
regular use of medication will be reflected in the SHBG
levels. In Fig. 1, it is shown that E2 and E2 + MPA
treatments indeed resulted in a significant increase in serum
SHBG levels in all, except one, subjects, while tibolone
treatment resulted in a significant decrease in SHBG levels
in all treated subjects.
Similarity and correlation between expression profiles
Cluster and correlation analysis allows us to visually assess
the similarity between and within groups. The unsupervised
cluster analysis (Fig. 2a) show that endometrial profiles of
control and E2 + MPA treated patients cluster together. The
fact that control samples cluster in two subgroups indicates
a high intra-individual variation. The endometrial profiles
of tibolone- and E2-treated patients form the second main
cluster. In this cluster, most endometrial profiles from
tibolone- and E2-treated patients separate in two subclus-
ters, indicating a higher profile correlation within both
treatment groups than between treatment groups.
In order to measure the magnitude of profile similarity
between treated individual patients and thus further differ-
entiate our analysis, a correlation analysis was performed
(Fig. 2b) and the average correlation data (calculated from
the individual correlations depicted in Fig. 2b) per group
are summarized in Table 1. When we only consider those
average correlations which deviate from zero, it is observed
that the endometrial profiles from E2-treated patients are
negatively correlated to the endometrial profiles from
control (−0.26±0.13) and E2 + MPA (−0.25±0.07) treated
patients and slightly positively correlated to the endometrial
profiles from tibolone (+0.18±0.17) treated patients. Fur-
thermore, the endometrial profiles from tibolone-treated
patients show a small negative correlation to the profiles
from E2 + MPA (−0.17±0.13) treated patients. These
correlation values support and further refine the cluster
outcome. Furthermore, high intra-individual variation was
observed within all groups.
Identification of genes with significant differential
expression
To take the analysis one step further, SAM analysis was
used to identify genes showing significant differential
expression in each treatment group relative to control and
relative to each other. The result is summarized in Table 2.
Relative to the control group, 799 genes are regulated in the
endometria of E2-treated patients, whereas 173 genes are
significantly regulated in endometria from tibolone-treated
Table 1 Correlations between the different treatments
Average of
correlations
Control Max Min E2 + MPA Max Min E2 Max Min Tibolone Max Min
Control +0.34
(±0.16)
0.63 0.04 +0.04(±0.14) 0.38 −0.17 −0.26(±0.13) 0.05 −0.44 −0.12(±0.18) 0.27 −0.39
E2 + MPA +0.46(±0.12) 0.63 0.23 −0.25(±0.07) −0.01 −0.40 −0.17(±0.13) 0.08 −0.40
E2 +0.55(±0.10) 0.77 0.32 +0.18(±0.17) 0.53 −0.27
Tibolone +0.36(±0.28) 0.61 −0.09
Average correlations calculated from the individual correlations depicted in Fig. 2a. Max represents the highest calculated individual correlation
coefficient; min represents the lowest calculated correlation coefficient. All average correlations were calculated ±SD.
Table 2 Number of significantly differentially regulated genes in
each treatment group
E2 +M P A E 2 Tibolone
Up Down Up Down Up Down
82 93 535 265 146 28
E2 + MPA Up 82 15 1 8 0
Down 93 0 27 0 9
E2 Up 535 55 0
Down 265 0 17
Treatment-
specific
Up 63 470 88
Down 63 226 8
The number of significantly differentially regulated genes in each
treatment group was identified relative to controls using SAM
analysis. The overlap in gene lists between different treatment groups
is shown. The numbers in italics indicate genes that are uniquely
regulated by a specific treatment. Furthermore, five genes were
upregulated by E2, E2 + MPA, and tibolone, and six genes were
downregulated by all three treatments.
J Mol Med (2007) 85:471–480 475476 J Mol Med (2007) 85:471–480patients, and 174 genes are significantly regulated in
endometria from E2 + MPA treated patients. These results
indicate that E2 treatment has a much higher impact on
endometrial RNA expression than the other treatments.
Upon evaluating the overlap in signaling, it was observed
that 9% of E2-regulated genes are also regulated by tibolone
(72 out of 799) and 5% are also regulated by E2 + MPA
treatment (43 out of 799). The overlap between tibolone
and E2 + MPA treatment is about 10% (17 out of 173) and
between tibolone and E2 treatment is 42% (72 out of 173).
Most regulated genes, however, are not regulated by more
than one treatment. These results indicate that all three
treatments result in modulation of expression of, for the
majority, uniquely regulated genes (the numbers of unique-
ly regulated genes are indicated by the italicized numbers in
Table 2) and that a subset of tibolone-regulated genes
(42%) overlaps with a limited fraction (9%) of E2-regulated
genes. The gene list resulting from the SAM analysis is
posted at http://www2.eur.nl/fgg/rede/hanifi_moghaddam/.
Functional and biological classification of genes
To gain insight into biological processes affected by the
different hormonal treatments (relative to control), genes
Real Time RT-PCR
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Fig. 4 Array data compared to
RT-PCR results. The array sig-
nal intensities (top) of tested
genes were normalized relative
to GAPDH. The RT-PCR sig-
nals (bottom) were normalized
relative to 18sRNA signals.
Solid black bars represent data
from control patients, solid
white bars represent data from
tibolone-treated patients, dashed
gray bars represent data from
E2 + MPA treated patients, and
the solid gray bars represent
data from E2-treated patients
Fig. 3 A gene expression network of E2- and tibolone-regulated
genes involved in the regulation of the cell cycle. From top to bottom,
genes are acting in extracellular space, plasma membrane, cytoplasm,
or nucleus. The colors indicate upregulation (red), downregulation
(green) or no regulation (not colored). The intensity of colors indicates
the magnitude of regulation (darker means more pronounced).
Relations between genes are indicated with gray lines and functions
of genes by the shape of the gene name boxes. Rectangle Nuclear
receptor, square cytokine, vertical diamond enzyme, horizontal
diamond peptidase, triangle kinase, quadrangle transporter, ellipse
transcription factor, circle other function
J Mol Med (2007) 85:471–480 477significantly regulated in each treatment group were classi-
fied into biological processes (Supplementary Table 3 posted
at http://www2.eur.nl/fgg/rede/hanifi_moghaddam/).
The overlap between E2 and tibolone treatment was
further evaluated at the level of the cell cycle. In total 112
cell cycle genes were regulated by E2 (87 genes upregu-
lated, 25 genes downregulated). The E2 treatment shared
only 18 genes with the tibolone treatment (a total of 22 cell
cycle genes were regulated by tibolone treatment). In Fig. 3
most of these data were placed in a gene expression
network containing information on the gene name, degree
of downregulation or upregulation, general function, con-
nectivity to other genes in the network, and general site of
action. As indicated by number of regulated genes and the
intensities of the colors in Fig. 3, it is clear that E2 treatment
has a far more pronounced effect on cell cycle genes than
tibolone. Survey of the overlapping genes showed that the
majority of genes belonged to the families of enzymes and
transcription regulators, and out of the 15 transcription
regulators that were regulated by E2, only one was also
regulated by tibolone treatment (Fig. 3). The gene list used
to generate Fig. 3 is posted at http://www2.eur.nl/fgg/rede/
hanifi_moghaddam/.
Verification of array results
In Fig. 4, the average outcomes of the quantitative PCR
analysis on CCND1, TFF3, IGFBP3, IGF1, VEGF, CSPG2,
ERα,E R β, PRB, and HSD17B2 are compared to the
average outcomes of the microarray experiments. Although
the absolute values cannot be compared, it was observed
that the RT-qPCR values resembled the microarray data
quite well.
Discussion
The current study is part of a multidisciplinary effort
(histological, biochemical, and molecular) to document short-
term (21 days) effects of tibolone on the human postmeno-
pausalendometrium,incomparisontotheeffectsofshort-term
E2 and E2 + MPA treatments. In this report we show for the
first time that the 21-day treatment of postmenopausal
patients with E2, E2 + MPA, or tibolone results in unique
changes in the endometrial gene expression profiles.
Gene expression profiles and regulated processes
Based on the results of cluster and correlation analyses, we
showed that the endometrial profiles after tibolone treat-
ment display a weak similarity to the profiles after E2
treatment and no similarity to control profiles or profiles
after E2 + MPA treatment. Upon analyzing the actual
numbers of significantly regulated genes and the overlap in
gene regulation between the treatments, this observation
could be refined further. Based on the number of regulated
genes, it was determined that the impact of E2 treatment
(799 significantly regulated genes) on endometrial gene
expression was much more pronounced than the impact of
the E2 + MPA (174 significantly regulated) or tibolone (173
significantly regulated genes) treatments. Furthermore, all
treatments resulted in regulation of mostly treatment-
specific genes: 87% (695 out of 799) of E2-regulated genes
were E2-specific, 72% (125 out of 174) of E2 + MPA
regulated genes were treatment-specific, and 55% (95 out
of 173) of tibolone regulated genes were tibolone-specific.
The overlap in gene regulation between the treatments
showed the highest overlap between tibolone- and E2-
regulated genes. The absolute number of overlapping genes
is 72, which represents 42% of tibolone regulated genes,
but only 9% of E2 regulated genes. This indicates that
tibolone treatment results in regulation of a minor subset of
E2-regulated genes. It should also be noted in this respect
that the fold modulation of these tibolone/E2-regulated
genes is much more pronounced in the endometria of E2-
treated women (average fold induction is 2.93) than in the
endometria of the tibolone-treated women (average fold
induction is 1.97).
Subsequently, the regulated genes were classified into
biological processes. Treatment of women with E2 + MPA
does not result in the regulation of any, by the Panther
database predefined, biological processes. This result was
not totally unexpected because cluster and correlation
analysis grouped the endometrial profiles after E2 + MPA
treatment with the endometrial profiles of untreated women
(control). However, upon a gene to gene base review of
expression, we could show specific regulation of a number
of implantation- and decidualization-related genes: fibrillin
[20], hydroxyprostaglandin dehydrogenase [21], glycodelin
[22], IGFBP1 [23], LEFTY2 [24], osteopontin [25],
granzymeA and B [26], glutathione peroxidase [27] and
more. Regulation of these genes is consistent with a
profound effect of progesterone on implantation and early
pregnancy.
It was also shown that tibolone and E2 treatments result
in significant regulation of processes involved in cell cycle
regulation. Upon placing the E2- and tibolone-regulated
genes involved in cell cycle regulation in one gene
expression network, it becomes clear that estrogens regulate
the cell cycle far more extensively than tibolone does.
Comparing the molecular data with earlier assessed
histological data
Before treatment started, all patients were assessed as
postmenopausal with an inactive endometrium. Upon
478 J Mol Med (2007) 85:471–480measuring endometrial thickness after treatment, effects of
the hormonal substitutions were observed [14]. Endometrial
thickness increased by 0.5 mm to 1.0 mm (±0.1) after
tibolone treatment, increased to 1.1 mm ((±0.6) after E2 +
MPA treatment, and increased to 2.6 mm ((±1.6) after E2
treatment. Assessment of proliferation showed an atrophic/
inactive endometrium in the control and E2 + MPA group.
Tibolone treatment resulted in a small stimulation, while the
endometria of E2-only treated women displayed pro-
nounced stimulation. Using Ki67 staining (a marker for
mitotic activity), the increment in proliferation could be
assessed. In tibolone-treated endometria in comparison to
control, Ki67 showed 3.5-fold more staining in stromal and
approximately the same staining in glandular cells. For E2 +
MPA treatment, these figures were 6.5-fold more in
stromal and 0.5-fold less in glandular cell, while for E2-
only treatment, again there was pronounced stimulation:
26.5-fold more staining in stromal cells and 6.6-fold more
staining in glandular cells (microarrays showed significant
upregulation of MKI67 only in E2 treated patients). The
overall conclusion of the histological evaluation was that
short-term (21 days) tibolone and E2 + MPA treatments
resulted in a small stimulation of proliferation of mostly the
stromal compartment of the endometrium, and that this
stimulation clearly differed from E2 stimulation of the
endometrium. Furthermore, it was also clear that the
tibolone and E2 + MPA treatments did not display exactly
the same effects on the endometria. Upon comparing the
histological findings with the currently discussed molecular
findings it is clear that both sets of data, for most part, result
in very similar conclusions.
Comparing the molecular data with earlier assessed
biochemical [15] data
During passage through the liver and gastrointestinal tract,
tibolone is converted into three metabolites: two hydroxy
metabolites, 3α-OH-tibolone and 3β-OH-tibolone (exerting
estrogenic effects), and the Δ
4-isomer (exerting progesta-
genic and androgenic effects) [7, 9]. Hormone measurements
showed that the metabolite patterns of tibolone in myome-
trium (due to tissue shortage the myometrial layer just
beneath the endometrium was used for measuring hormones)
are different from those in serum [15]. Whereas low levels of
bioactive metabolites (unconjugated) are found in serum,
Δ
4-isomer levels are high in the myometrium of most
women. This indicates that biochemically in serum, tibolone
displays weak estrogenic activity, while in the uterus,
tibolone progestagenic activities are more pronounced. This
biochemical finding is of interest because it may help explain
why the short-term effects of tibolone on gene expression are
pronouncedly different from the effects of E2 alone and also
different from the effects of E2 + MPA.
In summary, by making use of state of the art
bioinformatic tools, a detailed analysis could be conducted,
which refined our initial cluster analysis and showed that
tibolone signaling displays a very limited overlap with
estrogen signaling, that tibolone displays no overlap with
E2 + MPA signaling, and that tibolone treatment results
mostly in regulation of a treatment-specific set of genes in
the endometrium. Furthermore, the current data are in
agreement with the earlier published histological assess-
ment of the same endometrial tissues and seem to be
supported by the biochemical assessment of the metabolites
of tibolone.
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